

WEST

Generate Collection

Print

L2: Entry 1 of 6

File: USPT

Sep 5, 2000

DOCUMENT-IDENTIFIER: US 6114388 A

TITLE: Monofunctional and/or polyfunctional polylysine conjugates

Brief Summary Paragraph Right (27):

The indolealkylamines and catecholamines used within the framework of the invention include especially tryptophan, 5-methoxytryptophan, serotonin, tryptamine, 5-methoxytryptamine, melatonin, phenylalanine, 3,4-dihydroxyphenylalanine and tyrosine.

Brief Summary Paragraph Right (47):

The conjugates according to the invention can be used especially for the preparation of pharmaceutical compositions or combinations which are useful in the treatment of neuronal degeneration, infectious, traumatic and toxic neuropathies, degenerative diseases of the autoimmune type, neurodegenerative disorders resulting from genetic diseases, and proliferative diseases, and more particularly in the following indications: memory disorders, vascular dementia, postencephalitic disorders, postapoplectic disorders, post-traumatic syndromes due to a cranial traumatism, disorders derived from cerebral anoxia, Alzheimer's disease, senile dementia, subcortical dementia such as Huntington's chorea and Parkinson's disease, dementia caused by AIDS, neuropathies derived from morbidity or damage to the sympathetic or sensory nerves, brain diseases such as cerebral edema, spinocerebellar degenerations, neuropathies resulting from Lyme disease, diseases presenting neurodegenerative disorders, such as Charcot-Marie-Tooth disease, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy, migraine, polyarthritis, insulin-dependent diabetes, systemic lupus erythematosus, Hashimoto's thyroiditis, Horton's disease, dermatomyositis and polymyositis, as well as ankylosing spondylarthritis, HIV infection and cancer.

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 6 of 6 returned.**☐ 1. Document ID: US 6114388 A

L2: Entry 1 of 6

File: USPT

Sep 5, 2000

US-PAT-NO: 6114388

DOCUMENT-IDENTIFIER: US 6114388 A

TITLE: Monofunctional and/or polyfunctional polylysine conjugates

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC
Draw Desc	Image										

☐ 2. Document ID: US 5965555 A

L2: Entry 2 of 6

File: USPT

Oct 12, 1999

US-PAT-NO: 5965555

DOCUMENT-IDENTIFIER: US 5965555 A

TITLE: Xanthine compounds having terminally animated alkynol side chains

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC
Draw Desc	Image										

☐ 3. Document ID: US 5780470 A

L2: Entry 3 of 6

File: USPT

Jul 14, 1998

US-PAT-NO: 5780470

DOCUMENT-IDENTIFIER: US 5780470 A

TITLE: Melatonergic indanyl piperazines

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC
Draw Desc	Image										

☐ 4. Document ID: US 5703239 A

L2: Entry 4 of 6

File: USPT

Dec 30, 1997

US-PAT-NO: 5703239

DOCUMENT-IDENTIFIER: US 5703239 A

TITLE: Indanylpiperidines as melatonergic agents

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC
Draw Desc	Image										

☐ 5. Document ID: EP 1161948 A2

L2: Entry 5 of 6

File: DWPI

Dec 12, 2001

DERWENT-ACC-NO: 2002-107865

DERWENT-WEEK: 200215

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Use of melatonin in manufacture of pharmaceutical or food composition for treatment or prevention of brain edema

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC
Draw Desc	Image										

☐ 6. Document ID: AU 200065951 A, WO 200113950 A1, JP 2001131089 A

L2: Entry 6 of 6

File: DWPI

Mar 19, 2001

DERWENT-ACC-NO: 2001-257591

DERWENT-WEEK: 200136

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Percutaneous absorption agent for melatonin receptor agonist comprises fatty acid ester, polyol and nonionic surfactant, useful for treating e.g. Alzheimer's disease and cerebral vascular disorders

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC
Draw Desc	Clip Img	Image									

Generate Collection

Print

Terms	Documents
L1 and melatonin	6

Display Format:

-

Change Format

[Previous Page](#)[Next Page](#)

WEST

Generate Collection

Print

L4: Entry 16 of 17

File: JPAB

Dec 17, 1996

DOCUMENT-IDENTIFIER: JP 08333346 A

TITLE: PYRAZOLIDINE DERIVATIVE AND FREE RADICAL SCAVENGER AND ISCHEMIC REPERFUSION
HINDARANCE INHIBITORAbstract (1):

PURPOSE: To obtain the subject new compound useful for brain edema, cerebral infarction, cardiac infarction, arrhythmia, etc., as a free radical scavenger, having antioxidant action and lipid peroxidation suppressing action and having high safety.

WEST

Generate Collection

Print

L4: Entry 15 of 17

File: USPT

Aug 11, 1992

DOCUMENT-IDENTIFIER: US 5137871 A

TITLE: Treatment to reduce edema for brain and musculature injuries

Brief Summary Paragraph Right (18):

Brain edema refers to a condition in which there is increased water content in brain tissues. This condition occurs when there is a breakdown in the function of blood vessels that normally separate blood constituents from brain tissues. Brain blood vessels become more permeable when they are injured by a lack of oxygen, by toxic substances generated in injured tissues, or by unknown causes such as those associated with brain hemorrhage of the newborn. The medical conditions associated with brain edema are: brain ischemia, brain infarction, brain tumors, brain infections and abscesses, brain trauma and contusions, and secondary brain damage arising from neurosurgical operations. Spinal cord injuries pose similar problems to brain damage, and the spinal cord is, like brain cells, nervous tissue.

WEST

Generate Collection

Print

L4: Entry 15 of 17

File: USPT

Aug 11, 1992

DOCUMENT-IDENTIFIER: US 5137871 A

TITLE: Treatment to reduce edema for brain and musculature injuries

Brief Summary Paragraph Right (18):

Brain edema refers to a condition in which there is increased water content in brain tissues. This condition occurs when there is a breakdown in the function of blood vessels that normally separate blood constituents from brain tissues. Brain blood vessels become more permeable when they are injured by a lack of oxygen, by toxic substances generated in injured tissues, or by unknown causes such as those associated with brain hemorrhage of the newborn. The medical conditions associated with brain edema are: brain ischemia, brain infarction, brain tumors, brain infections and abscesses, brain trauma and contusions, and secondary brain damage arising from neurosurgical operations. Spinal cord injuries pose similar problems to brain damage, and the spinal cord is, like brain cells, nervous tissue.

WEST

Generate Collection

Print

L4: Entry 13 of 17

File: USPT

May 28, 1996

DOCUMENT-IDENTIFIER: US 5520912 A

TITLE: Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen

Brief Summary Paragraph Right (13):

Venous occlusion can cause massive damage and death. This disease is less common than arterial cerebral vascular disease. As with ischemic stroke from arterial disease, the primary mechanism of brain damage is the reduction in capillary blood flow, in this instance because of increased outflow resistance from the blocked veins. Back transmission of high pressure into the capillary bed usually results in early brain swelling from edema and hemorrhagic infarction in subcortical white matter. The most dangerous form of venous disease arises when the superior sagittal sinus is occluded. Venous occlusion occurs in association with coagulation disorders, often in the purpural period, or in subjects with disseminated cancers or contagious diseases. If anticoagulant therapy is not initiated, superior sagittal sinus occlusion has a mortality rate of 25-40%.

WEST

Generate Collection

Print

L4: Entry 9 of 17

File: USPT

Oct 6, 1998

DOCUMENT-IDENTIFIER: US 5817684 A

TITLE: Leukotriene antagonists for use in the treatment or inhibition of cerebral focal stroke

Brief Summary Paragraph Right (13):

Venous occlusion can cause massive damage and death. This disease is less common than arterial cerebral vascular disease. As with ischemic stroke from arterial disease, the primary mechanism of brain damage is the reduction in capillary blood flow, in this instance because of increased outflow resistance from the blocked veins. Back transmission of high pressure into the capillary bed usually results in early brain swelling from edema and hemorrhagic infarction in subcortical white matter. The most dangerous form of venous disease arises when the superior sagittal sinus is occluded. Venous occlusion occurs in association with coagulation disorders, often in the purpural period, or in subjects with disseminated cancers or contagious diseases. If anticoagulant therapy is not initiated, superior sagittal sinus occlusion has a mortality rate of 25-40%.

WEST

Generate Collection

Print

L4: Entry 8 of 17

File: USPT

Dec 15, 1998

DOCUMENT-IDENTIFIER: US 5849930 A

TITLE: Pyrazolidine derivative radical scavenger brain-infarction depressant and brain-edema depressant

Brief Summary Paragraph Right (5):

In view of the foregoing prior art, an object of the present invention is to provide a low-molecular compound which is, as a radical scavenger, effective against brain edema and brain infarction.

Brief Summary Paragraph Right (7):

As a result of diligent studies of the inventors for attaining the above mentioned objects, it has been found that a specific pyrazolidine derivative and its pharmacologically acceptable salts are effective, as a radical scavenger, against brain edema and brain infarction, thereby accomplishing the present invention.

Brief Summary Paragraph Right (26):

The pyrazolidine derivative and its pharmacologically acceptable salts in accordance with the present invention, as a radical scavenger, have antioxidant effect and lipid peroxidation suppressing effect as well as a high safety. Accordingly, they are effective as medicaments for preventing and curing various damages attributable to radicals generated by ischemic reperfusion or the like such as brain infarction and brain edema. Also, they are expected to be effective against myocardial infarction and arrhythmia. Further, unlike the conventional radical scavengers, some kinds of the compound of the present invention have been found to be effective, by one drug, against both brain edema and brain infarction.

Detailed Description Paragraph Right (31):

As can be seen from the foregoing examples, the materials belonging to this group has a high DPPH reducing effect (radical-eliminating effect) as well as a lipid peroxidation inhibitory activity. Also, the compound of Example 7, for example, exhibits an excellent effect of inhibition both brain infarction and brain edema. Such a compound, which is effective against both brain edema and brain infarction alone, is quite rare.

WEST

Generate Collection

Print

L4: Entry 1 of 17

File: USPT

Dec 18, 2001

US-PAT-NO: 6331553

DOCUMENT-IDENTIFIER: US 6331553 B1

TITLE: Aromatic amine derivatives having NOS inhibiting action

DATE-ISSUED: December 18, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Esaki; Toru	Shizuoka-ken			JPX
Makino; Toshihiko	Shizuoka-ken			JPX
Nishimura; Yoshikazu	Shizuoka-ken			JPX
Nagafuji; Toshiaki	Shizuoka-ken			JPX

ASSIGNEE-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY	TYPE CODE
Chugai Seiyaku Kabushiki Kaisha	Tokyo			JPX	03

APPL-NO: 9/ 331733 [PALM]

DATE FILED: June 24, 1999

PARENT-CASE:

CROSS REFERENCE TO RELATED APPLICATION The present application is the national stage under 35 U.S.C. 371 of PCT/JP97/04762, filed Dec. 24, 1997.

FOREIGN-APPL-PRIORITY-DATA:

COUNTRY	APPL-NO	APPL-DATE
JP	8-359791	December 24, 1996

PCT-DATA:

APPL-NO	DATE-FILED	PUB-NO	PUB-DATE	371-DATE	102 (E) -DATE
PCT/JP97/04762	December 24, 1997	WO98/28257	Jul 2, 1998	Jun 24, 1999	Jun 24, 1999

INT-CL: [7] C07 D 213/02, A61 K 31/44

US-CL-ISSUED: 514/352; 514/272, 514/370, 514/377, 514/658, 544/330, 546/304, 564/433, 548/190, 548/234

US-CL-CURRENT: 514/352; 514/272, 514/370, 514/377, 514/658, 544/330, 546/304, 548/190, 548/234, 564/433

FIELD-OF-SEARCH: 546/304, 514/352, 514/370, 514/377, 514/272, 514/658, 564/433, 544/330, 548/190, 548/234

PRIOR-ART-DISCLOSED:

FOREIGN PATENT DOCUMENTS

FOREIGN-PAT-NO	PUBN-DATE	COUNTRY	US-CL
6192080	July 1994	JPX	
9505363	February 1995	WOX	
9509619	April 1995	WOX	

OTHER PUBLICATIONS

International Search Report for PCT/JP97/04762, 1998.*

Matsui et al., "Participation of nitric oxide in pathogenetics mechanism underlying brain damage" JIKKEN IGAKU, vol. 11, pp. 2457-2462, (1995).

Matsui et al., "Increase notric oxide production mediates ischemic brain damage", JIKKEN IGAKU, vol. 13 pp. 1011-1019, (1995).

Nathan, "Nitric oxide as a secretory product of mammalian cells", FASEB J., vol. 6, pp. 3051-3064, (1992).

Nagafuji et al., "Nitric Oxide Synthase in Cerebral Ischemia", Molecular and Chemical Neuropathology, vol. 26 pp. 107-157, (1995).

Siesjo, "Cell Damage in the Brain: A Speculative Synthesis", Journal of Cerebral Blood Flow and Metabolism vol. 1, pp. 155-185, (1981).

Siesjo, "Cerebral circulation and metabolism", J. Neurosurg, vol. 60, pp. 883-908, (1984).

Choi, "Calcium-mediated neurotoxicity:relationship to specific channel types and role in ischemic damage" Tins, vol. 11, No. 10, pp. 465-469, (1988).

Siesjo et al., "Calcium Fluxes, Calcium Antagonists, and Calcium-Related Pathology in Brain Ischemia, Hypoglycemia, and Spreading Depression: A Unifying Hypothesis", Journal of Cerebral Blood Flow and Metabolism vol. 9, pp. 127-140, (1989).

Dawson et al., "A Novel Neuronal Messenger Molecule in Brain: The Free Radical, Nitric Oxide", Annals of Neurology, vol. 32, No. 3, pp. 297-311, (1992).

Zhang et al., "Upregulation of neuronal nitric oxide synthase and mRNA, and selective sparing of nitric oxide synthase-containing neurons after focal cerebral ischemia in rat", Brain Res., vol. 645, pp. 85-95, (1994).

Carreau et al., "Neuroprotective efficacy of N- nitro -L-arginie after focal cerebral ischemia in the mouse and inhibition of cortical nitric oxide synthase", European Journal of Pharmacology, vol. 256, pp. 241-249 (1994).

Huang et al., "Effect of Cerebral Ischemia in Mice Deficient in Neuronal Nitric Oxide Synthase", Science vol. 265, pp. 1883-1885, (1994).

Moncada et al., Nitric Oxide:Physiology, Pathophysiology, and Pharmacology, Pharmacological Reviews, vol. 43 pp. 109-142, (1991).

Huang et al., "Enlarged Infarcts in Endothelial Nitric Oxide Synthase Knockout Mice Are Attenuated by Nitro-L-Arginine", Journal of Cerebral Blood Flow Meta olism, vol. 16, pp. 981-987, (1996).

Nagafuji et al., "Blockade of nitric oxide formation by N -nitro-L-argine mitigates ischemic brain edema and subsequent cerebral infarction in rats", vol. 147, pp. 159-162, (1992).

Nagafuji et al., "A narrow therapeutical window of a nitric oxide synthase inhibitor against transient ischemic brain injury", European Journal of Pharmacology, vol. 248, pp. 325-328, (1993).

Iadecola et al., "Nitric Oxide Synthase Inhibition and Cerebrovascular Regulation", Journal of Cerebral Blood Flow and Metabolism, vol. 14, pp. 175-192, (1994).

Nagafuji et al., "The neuroprotective effect of a potent and selective inhibitor of type I NOS (L-MIN) in a model of focal cerebral ischaemia", Neuroreport, vol. 6, pp. 1541-1545, (1995).

Nowicki et al., "Nitric oxide mediates neuronal death after focal cerebral ischemia in the mouse", European Journal of Pharmacology, vol. 204, pp. 339-340, (1991).

Dawson et al., "Nitric oxide mediated glutamate neurotoxicity in primary cortical cultures", Proc. Natl. Acad Sci., vol. 88, pp. 6368-6371, (1991).

Iadecola et al., "Marked Induction of Calcium-Independent Nitric Oxide Synthase Activity After Focal Cerebral Ischemia", Journal of Cerebral Blood Flow and Metabolism, vol. 15, pp. 52-59, (1995).

Iadecola et al., "Inducible Nitric Oxide Synthase Gene Expression in Brain Following Cerebral Ischemia" Journal of Cerebral Blood Flow and Metabolism, vol. 15, pp. 378-384, (1995).

Cury et al., "Cold-induced Brain Edema in Mice", The Journal of Biological Chemistry, vol. 268, No. 21 pp. 15394-15398, (1993).

MacKenzie et al., "Effect of 7-nitro indazole on quinolinic acid-induced striatal

toxicity in the rat" *Neuroreport*, vol. 6, No. 13, pp. 1789-1794, (1995).

Mesenge et al., "Reduction of the Neurological Deficit in Mice with Traumatic Brain injury by Nitric Oxide Synthase Inhibitors", *Journal of Neurotrauma*, vol. 13, No. 1, pp. 11-17, (1996).

Wallis et al., "Traumatic neuroprotection with inhibitors of nitric oxide and ADP-ribosylation" *Brain Research*, vol. 710, pp. 169-177, (1996).

Moore et al., "L-N-nitro arginine methyl ester exhibits antinociceptive activity in the mouse", *Br. J. Pharm.* vol. 102, pp. 198-202, (1991).

Olesen et al., "Nitric oxide is a key molecule in migraine and other vascular headaches", *Trends Pharm.* vol. 15, pp. 149-153, (1994).

Youdim et al., "The Neurotoxicity of Iron and Nitric Oxide", *Advances in Neurology*, vol. 60, pp. 259-266 (1993).

Schulz et al., "Inhibition of Neuronal Nitric Oxide Synthase by 7-Nitroindazole Protects Against MPTP-Induced Neurotoxicity in Mice", *Journal of Neurochemistry*, vol. 64, pp. 936-939, (1995).

Haniraye et al., "Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons" *Nature Medicine*, vol. 2, No. 9, pp. 1017-1021, (1996).

Hu et al., "Amyloid 25-35 activates nitric oxide synthase in a neuronal clone", *NeuroReport*, vol. 4, No. 6 pp. 760-762, (1993).

Meda et al., "Activation of microglial cells by α -amyloid proteins and interferon", *Nature*, vol. 374, pp. 647-650, (1995).

Monnet et al., "Blockade of Nitric Oxide Synthase Inhibits Hippocampal Hyperemia in Kainic Acid-Induced Seizures", *Journal of Cerebral Blood Flow and Metabolism*, vol. 14, pp. 581-590, (1994).

Kolesnikov et al., "N-Nitro-L-arginine prevents morphine tolerance", *European Journal of Pharmacology* vol. 221, pp. 399-400, (1992).

Cappendijk et al., "Inhibitory effect of nitric oxide (NO) synthase inhibitors on naloxone-precipitated withdrawal syndrome in morphine-dependent mice", *Neuroscience Letters*, vol. 162, pp. 97-100, (1993).

Kilbourn et al., "Overproduction of Nitric Oxide in Cytokine-Mediated and Septic Shock", *Journal of the Cancer Institute*, vol. 84, No. 11, pp. 827-831, (1992).

Cobb et al., "Nitric oxide as a target for therapy in septic shock", *Critical Care Medicine*, vol. 21, No. 9 pp. 1261-1263, (1993).

Lorenz et al., "L-arginine pathway in the sepsis syndrome", *Critical Care Medicine*, vol. 21, No. 9, pp. 1287-1295, (1993).

Farrell et al., "Increased concentrations of nitrite in synovial fluid and serum sample suggest increased nitric oxide synthesis in rheumatic diseases", *Annals of the Rheumatic Diseases*, vol. 51, pp. 1219-1222, (1992).

Matsuzake et al., "Generation of the topa quinone cofactor in bacterial monoamine oxidase by cupric ion-dependent autooxidation of a specific tyrosyl residue", *FEBS Letters*, vol. 351, pp. 360-364, (1994).

Talenti et al., "Modulation of Adjuvant arthritis by endogenous nitric oxide", *Br. J. Pharmacol.*, vol. 110 pp. 701-706, (1993).

Zembowicz et al., "Induction of nitric oxide synthase activity by toxic shock syndrome toxin 1 in a macrophage-monocyte cell line", *Proc. Natl. Acad.*, vol. 89, pp. 2051-2055, (1992).

Koprowski et al., "In vivo expression of inducible nitric oxide synthase in experimental ally induced neurologic diseases", *Proc. Natl. Acad.*, vol. 90, pp. 3024-3027, (1993).

Kolb et al., "Suppression of low Dose streptozotocin induced diabetes in mice by administration of a nitric oxide synthase inhibitor", *Life Science*, vol. 49, pp. PL-213-PL-217, (1991).

Lambert et al., "Characterization of cell selectivity of two novel inhibitors of nitric oxide synthesis" *European Journal of Pharmacology*, vol. 216, pp. 131-134, (1992).

Furfin et al., "Selective Inhibition of Constitutive Nitric Oxide Synthase by L-N-Nitroarginine" *Biochemistry*, vol. 32, pp. 8512-8517, (1993).

Narayanan et al., "Synthesis of L-Thiocitrulline, L-Homothiocitrulline, and S-Methyl-L-thiocitrulline: A new Class of Protein Nitric Oxide Synthase Inhibitors", *J. Med. Chem.*, vol. 37, pp. 885-887, (1994).

Furfin et al., "Potent and Selective Inhibition of Human Nitric Oxide Synthases", *The Journal of Biological Chemistry*, vol. 269, pp. 26677-26683, (1994).

Narayanan et al., "S-Alkyl-L-thiocitrullines", *The Journal of Biological Chemistry*, vol. 270, No. 19, pp. 11103-11110, (1995).

Zhang et al., "ARL 17477, a Potent and Selective Neuronal NOS Inhibitor Decreases

Infarct Volume After Transient Middle Cerebral Artery Occlusion in Rats", Journal of Cerebral Blood Flow and Metabolism, vol. 16 pp. 599-604, (1996).
McCall et al., "Identification of N-iminoethyl-L-amithine as an irreversible inhibitor of nitric oxide synthase in phagocytic cells", Br. J. Pharm., vol. 102, pp. 234-238, (1991).
Griffiths et al., "Aminoguanidine selectively inhibits inducible nitric oxide synthase", Br. J. Pharm. vol. 110, pp. 963-968, (1993).
Hasan et al., "Inhibition of nitric oxide formation by guanidines", European Journal of Pharm., vol. 249 pp. 101-106, (1993).
Dressman et al., "Solid Phase Synthesis of Hydantions Using a Carbamate Linker and a Novel Cyclization/Cleavage Step", Tetrahedron Letters, vol. 37, No. 7, pp. 937-940, (1996).

ART-UNIT: 162

PRIMARY-EXAMINER: Davis; Zinna Northington

ATTY-AGENT-FIRM: Browdy and Neimark

ABSTRACT:

Compounds represented by the general formula (1): ##STR1##

(where R.sub.1 and R.sub.2 are typically a hydrogen atom; R.sub.3 and R.sub.4 are typically a hydrogen atom or a lower alkyl group; R.sub.5 is typically a hydrogen atom; X.sub.1, X.sub.2, X.sub.3 and X.sub.4 are typically a hydrogen atom or a lower alkoxy group; A is typically an optionally substituted pyridine ring; m and n are each 0 or 1) have an NOS inhibiting activity and are useful as therapeutics of cerebrovascular diseases and other pharmaceuticals.

43 Claims, 0 Drawing figures

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 17 of 17 returned.**☐ 1. Document ID: US 6331553 B1

L4: Entry 1 of 17

File: USPT

Dec 18, 2001

US-PAT-NO: 6331553

DOCUMENT-IDENTIFIER: US 6331553 B1

TITLE: Aromatic amine derivatives having NOS inhibiting action

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMIC
Draw Desc	Image										

☐ 2. Document ID: US 6265443 B1

L4: Entry 2 of 17

File: USPT

Jul 24, 2001

US-PAT-NO: 6265443

DOCUMENT-IDENTIFIER: US 6265443 B1

TITLE: Method for treating neuronal injury with carboxyfullerene

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMIC
Draw Desc	Image										

☐ 3. Document ID: US 6194899 B1

L4: Entry 3 of 17

File: USPT

Feb 27, 2001

US-PAT-NO: 6194899

DOCUMENT-IDENTIFIER: US 6194899 B1

TITLE: Temperature monitoring method, temperature monitoring apparatus and magnetic resonance apparatus

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMIC
Draw Desc	Image										

☐ 4. Document ID: US 6124351 A

L4: Entry 4 of 17

File: USPT

Sep 26, 2000

US-PAT-NO: 6124351

DOCUMENT-IDENTIFIER: US 6124351 A

TITLE: Amino acid derivatives having a nitric oxide synthase inhibiting action

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC
Draw Desc	Image										

☐ 5. Document ID: US 6083987 A

L4: Entry 5 of 17

File: USPT

Jul 4, 2000

US-PAT-NO: 6083987

DOCUMENT-IDENTIFIER: US 6083987 A

TITLE: Phenylenediamine derivative, radical scavenger, brain-infarction depressant, and brain-edema depressant

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments		KWIC
Draw Desc	Image										

☐ 6. Document ID: US 6071968 A

L4: Entry 6 of 17

File: USPT

Jun 6, 2000

US-PAT-NO: 6071968

DOCUMENT-IDENTIFIER: US 6071968 A

TITLE: Phenylenediamine derivative radical scavenger, brain-infarction depressant, and brain-edema depressant

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments		KWIC
Draw Desc	Image										

☐ 7. Document ID: US 5859308 A

L4: Entry 7 of 17

File: USPT

Jan 12, 1999

US-PAT-NO: 5859308

DOCUMENT-IDENTIFIER: US 5859308 A

TITLE: Transgenic animals and related aspects

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments		KWIC
Draw Desc	Image										

☐ 8. Document ID: US 5849930 A

L4: Entry 8 of 17

File: USPT

Dec 15, 1998

US-PAT-NO: 5849930

DOCUMENT-IDENTIFIER: US 5849930 A

TITLE: Pyrazolidine derivative radical scavenger brain-infarction depressant and brain-edema depressant

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMOC
Draw Desc	Image									

☐ 9. Document ID: US 5817684 A

L4: Entry 9 of 17

File: USPT

Oct 6, 1998

US-PAT-NO: 5817684

DOCUMENT-IDENTIFIER: US 5817684 A

TITLE: Leukotriene antagonists for use in the treatment or inhibition of cerebral focal stroke

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMOC
Draw Desc	Image									

☐ 10. Document ID: US 5801160 A

L4: Entry 10 of 17

File: USPT

Sep 1, 1998

US-PAT-NO: 5801160

DOCUMENT-IDENTIFIER: US 5801160 A

TITLE: Method of protecting brain tissue from cerebral infarction subsequent to ischemia

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMOC
Draw Desc	Image									

☐ 11. Document ID: US 5604210 A

L4: Entry 11 of 17

File: USPT

Feb 18, 1997

US-PAT-NO: 5604210

DOCUMENT-IDENTIFIER: US 5604210 A

TITLE: Inhibitor of vascular permeability enhancer

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMOC
Draw Desc	Image									

☐ 12. Document ID: US 5597800 A

L4: Entry 12 of 17

File: USPT

Jan 28, 1997

US-PAT-NO: 5597800

DOCUMENT-IDENTIFIER: US 5597800 A

TITLE: Treatment with lys-plasminogen of reperfusion injury and brain edema caused by ischemia

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KMIC

☐ 13. Document ID: US 5520912 A

L4: Entry 13 of 17

File: USPT

May 28, 1996

US-PAT-NO: 5520912

DOCUMENT-IDENTIFIER: US 5520912 A

TITLE: Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KMIC

☐ 14. Document ID: US 5306710 A

L4: Entry 14 of 17

File: USPT

Apr 26, 1994

US-PAT-NO: 5306710

DOCUMENT-IDENTIFIER: US 5306710 A

TITLE: Method for treating endotoxin shock with CRF

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KMIC

☐ 15. Document ID: US 5137871 A

L4: Entry 15 of 17

File: USPT

Aug 11, 1992

US-PAT-NO: 5137871

DOCUMENT-IDENTIFIER: US 5137871 A

TITLE: Treatment to reduce edema for brain and musculature injuries

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KMIC

☐ 16. Document ID: JP 08333346 A

L4: Entry 16 of 17

File: JPAB

Dec 17, 1996

PUB-NO: JP408333346A

DOCUMENT-IDENTIFIER: JP 08333346 A

TITLE: PYRAZOLIDINE DERIVATIVE AND FREE RADICAL SCAVENGER AND ISCHEMIC REPERFUSION HINDARANCE INHIBITOR

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KMIC

☐ 17. Document ID: EP 704215 A2

L4: Entry 17 of 17

File: EPAB

Apr 3, 1996

PUB-NO: EP000704215A2

DOCUMENT-IDENTIFIER: EP 704215 A2

TITLE: Inhibitor of vascular permeability enhancer

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

K/MC

Generate Collection

Print

Terms	Documents
(brain adj2 edema) adj5 infarction	17

Display Format:

-

Change Format

[Previous Page](#)

[Next Page](#)

WEST Search History

DATE: Monday, March 11, 2002

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
L4	(brain adj2 edema) adj5 infarction	17	L4
L3	L1 and infarction	392	L3
L2	L1 and melatonin	6	L2
L1	(brain or cerebral) adj2 edema	1149	L1

END OF SEARCH HISTORY

WEST

Generate Collection

Print

L5: Entry 42 of 66

File: USPT

Jan 28, 1997

DOCUMENT-IDENTIFIER: US 5597800 A

TITLE: Treatment with lys-plasminogen of reperfusion injury and brain edema caused by ischemia

CLAIMS:

6. A method of treating brain edema, comprising the step of administering to a subject having brain edema a pharmaceutical composition comprising lys-plasminogen in an amount sufficient to provide a lessening of brain edema caused by cerebral ischemia.

WEST

Generate Collection

Print

L5: Entry 53 of 66

File: USPT

Aug 11, 1992

DOCUMENT-IDENTIFIER: US 5137871 A

TITLE: Treatment to reduce edema for brain and musculature injuries

Brief Summary Paragraph Right (18):

Brain edema refers to a condition in which there is increased water content in brain tissues. This condition occurs when there is a breakdown in the function of blood vessels that normally separate blood constituents from brain tissues. Brain blood vessels become more permeable when they are injured by a lack of oxygen, by toxic substances generated in injured tissues, or by unknown causes such as those associated with brain hemorrhage of the newborn. The medical conditions associated with brain edema are: brain ischemia, brain infarction, brain tumors, brain infections and abscesses, brain trauma and contusions, and secondary brain damage arising from neurosurgical operations. Spinal cord injuries pose similar problems to brain damage, and the spinal cord is, like brain cells, nervous tissue.

WEST Search History

DATE: Monday, March 11, 2002

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
L6	L5 and melatonin	0	L6
L5	(brain adj2 edema) adj5 ischemia	66	L5
L4	(brain adj2 edema) adj5 infarction	17	L4
L3	L1 and infarction	392	L3
L2	L1 and melatonin	6	L2
L1	(brain or cerebral) adj2 edema	1149	L1

END OF SEARCH HISTORY

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 30 of 30 returned.**☐ 1. Document ID: US 6239162 B1

L1: Entry 1 of 30

File: USPT

May 29, 2001

US-PAT-NO: 6239162

DOCUMENT-IDENTIFIER: US 6239162 B1

TITLE: Method for treating depression

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC
Draw Desc	Image										

☐ 2. Document ID: US 6207190 B1

L1: Entry 2 of 30

File: USPT

Mar 27, 2001

US-PAT-NO: 6207190

DOCUMENT-IDENTIFIER: US 6207190 B1

TITLE: Dosage forms for the treatment of the chronic glaucomas

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC
Draw Desc	Image										

☐ 3. Document ID: US 6187750 B1

L1: Entry 3 of 30

File: USPT

Feb 13, 2001

US-PAT-NO: 6187750

DOCUMENT-IDENTIFIER: US 6187750 B1

TITLE: Method of hormone treatment for patients with symptoms consistent with multiple sclerosis

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC
Draw Desc	Image										

☐ 4. Document ID: US 6075045 A

L1: Entry 4 of 30

File: USPT

Jun 13, 2000

US-PAT-NO: 6075045

DOCUMENT-IDENTIFIER: US 6075045 A

TITLE: Method of treating paralysis of the extremities caused by cerebral infarction

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC
Draw Desc	Image										

☐ 5. Document ID: US 6069138 A

L1: Entry 5 of 30

File: USPT

May 30, 2000

US-PAT-NO: 6069138

DOCUMENT-IDENTIFIER: US 6069138 A

TITLE: Use of phospholipids of animal origin in therapy and/or dietetics

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC
Draw Desc	Image										

☐ 6. Document ID: US 6063805 A

L1: Entry 6 of 30

File: USPT

May 16, 2000

US-PAT-NO: 6063805

DOCUMENT-IDENTIFIER: US 6063805 A

TITLE: Method for treating hypertension

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC
Draw Desc	Image										

☐ 7. Document ID: US 6030641 A

L1: Entry 7 of 30

File: USPT

Feb 29, 2000

US-PAT-NO: 6030641

DOCUMENT-IDENTIFIER: US 6030641 A

TITLE: Sustained release capsule and method for preparing the same

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC
Draw Desc	Image										

☐ 8. Document ID: US 6011054 A

L1: Entry 8 of 30

File: USPT

Jan 4, 2000

US-PAT-NO: 6011054

DOCUMENT-IDENTIFIER: US 6011054 A

TITLE: Method for treating depression, obsessive compulsive disorder, and anxiety with N--acetyl serotonin

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 9. Document ID: US 5990094 A

L1: Entry 9 of 30

File: USPT

Nov 23, 1999

US-PAT-NO: 5990094

DOCUMENT-IDENTIFIER: US 5990094 A

TITLE: Inhibitors of sorotonin N-acetyltransferase

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 10. Document ID: US 5891465 A

L1: Entry 10 of 30

File: USPT

Apr 6, 1999

US-PAT-NO: 5891465

DOCUMENT-IDENTIFIER: US 5891465 A

TITLE: Delivery of biologically active material in a liposomal formulation for administration into the mouth

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 11. Document ID: US 5855920 A

L1: Entry 11 of 30

File: USPT

Jan 5, 1999

US-PAT-NO: 5855920

DOCUMENT-IDENTIFIER: US 5855920 A

TITLE: Total hormone replacement therapy

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 12. Document ID: US 5725558 A

L1: Entry 12 of 30

File: USPT

Mar 10, 1998

US-PAT-NO: 5725558

DOCUMENT-IDENTIFIER: US 5725558 A

TITLE: Device for influencing low-frequency electrical and magnetic fields

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 13. Document ID: US 5691325 A

L1: Entry 13 of 30

File: USPT

Nov 25, 1997

US-PAT-NO: 5691325

DOCUMENT-IDENTIFIER: US 5691325 A

TITLE: Method for ameliorating age-related disease conditions

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KIMC

☐ 14. Document ID: US 5500225 A

L1: Entry 14 of 30

File: USPT

Mar 19, 1996

US-PAT-NO: 5500225

DOCUMENT-IDENTIFIER: US 5500225 A

TITLE: Method for determination of urine components and for preventing sudden infant death syndrome

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KIMC

☐ 15. Document ID: US 4945103 A

L1: Entry 15 of 30

File: USPT

Jul 31, 1990

US-PAT-NO: 4945103

DOCUMENT-IDENTIFIER: US 4945103 A

TITLE: Method of treating pre-menstrual syndrome

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KIMC

☐ 16. Document ID: US 4882137 A

L1: Entry 16 of 30

File: USPT

Nov 21, 1989

US-PAT-NO: 4882137

DOCUMENT-IDENTIFIER: US 4882137 A

TITLE: Coated veterinary implants

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KIMC

☐ 17. Document ID: US 4746674 A

L1: Entry 17 of 30

File: USPT

May 24, 1988

US-PAT-NO: 4746674

DOCUMENT-IDENTIFIER: US 4746674 A

TITLE: Melatonin compositions and uses thereof

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 18. Document ID: US 4738679 A

L1: Entry 18 of 30

File: USPT

Apr 19, 1988

US-PAT-NO: 4738679

DOCUMENT-IDENTIFIER: US 4738679 A

TITLE: Veterinary implant

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 19. Document ID: US 4687763 A

L1: Entry 19 of 30

File: USPT

Aug 18, 1987

US-PAT-NO: 4687763

DOCUMENT-IDENTIFIER: US 4687763 A

TITLE: Composition and method for increasing levels or release of brain serotonin

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 20. Document ID: JP 10004953 A

L1: Entry 20 of 30

File: JPAB

Jan 13, 1998

PUB-NO: JP410004953A

DOCUMENT-IDENTIFIER: JP 10004953 A

TITLE: COMPOSITION FOR BEAUTY AND HEALTH UTILIZING MELATONIN YEAST

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 21. Document ID: JP 61221104 A

L1: Entry 21 of 30

File: JPAB

Oct 1, 1986

PUB-NO: JP361221104A
DOCUMENT-IDENTIFIER: JP 61221104 A
TITLE: SKIN COSMETIC

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMOC
Draw Desc	Image									

☐ 22. Document ID: US 5500225 A

L1: Entry 22 of 30

File: EPAB

Mar 19, 1996

PUB-NO: US005500225A
DOCUMENT-IDENTIFIER: US 5500225 A
TITLE: Method for determination of urine components and for preventing sudden infant death syndrome

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMOC
Draw Desc	Image									

☐ 23. Document ID: EP 1161948 A2

L1: Entry 23 of 30

File: DWPI

Dec 12, 2001

DERWENT-ACC-NO: 2002-107865
DERWENT-WEEK: 200215
COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Use of melatonin in manufacture of pharmaceutical or food composition for treatment or prevention of brain edema

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMOC
Draw Desc	Image									

☐ 24. Document ID: NZ 505361 A, EP 1064941 A1, AU 200042648 A, CA 2312432 A1, FR 2795323 A1, NO 200003108 A, BR 200002772 A, ZA 200003165 A, JP 2001026539 A, CN 1283455 A, KR 2001039680 A

L1: Entry 24 of 30

File: DWPI

Feb 1, 2002

DERWENT-ACC-NO: 2001-114031
DERWENT-WEEK: 200214
COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Use of melatonin or a melatoninerigic ligand in compositions for the prevention and treatment of gastrointestinal disorders

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMOC
Draw Desc	Image									

☐ 25. Document ID: AU 200023654 A, WO 200039777 A1

L1: Entry 25 of 30

File: DWPI

Jul 31, 2000

DERWENT-ACC-NO: 2000-679035

DERWENT-WEEK: 200066

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Computer implemented personal supplement regimen determination used in health counseling, involves generating list of supplements to be consumed by person, after computing information pertaining to person health

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Drawn Desc	Clip Img	Image							

KMIC

☐ 26. Document ID: KR 98049239 A

L1: Entry 26 of 30

File: DWPI

Sep 15, 1998

DERWENT-ACC-NO: 1999-491878

DERWENT-WEEK: 199941

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Method for preparing foodstuff containing natural melatonin by using lettuce - NoAbstract

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Drawn Desc	Image								

KMIC

☐ 27. Document ID: AU 9852607 A, WO 9821947 A1

L1: Entry 27 of 30

File: DWPI

Jun 10, 1998

DERWENT-ACC-NO: 1998-312037

DERWENT-WEEK: 199843

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Relief of night time persistent reproductive transition symptoms - i.e., menopausal disorders, using phytoestrogen, melatonin, and carbohydrate, optionally as food or drink product

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Drawn Desc	Image								

KMIC

☐ 28. Document ID: CN 1164422 A

L1: Entry 28 of 30

File: DWPI

Nov 12, 1997

DERWENT-ACC-NO: 2001-457909

DERWENT-WEEK: 200150

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Functional food for improving sleep

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KMIC

☐ 29. Document ID: US 5500225 A

L1: Entry 29 of 30

File: DWPI

Mar 19, 1996

DERWENT-ACC-NO: 1996-171003

DERWENT-WEEK: 199617

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Determn. of non-volatile organic components in urine of humans wearing diapers - by repeatedly removing soiled diaper, removing outer cover etc., estimating amt. of contained water and organic solvent extn. of weighed portion for assay

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KMIC

☐ 30. Document ID: CZ 288834 B6, EP 656209 A2, AU 9477776 A, NO 9404340 A, CA 2135710 A, CZ 9402764 A3, JP 07196504 A, EP 656209 A3, ZA 9408928 A, CN 1107700 A, NZ 264893 A, HU 72070 T, AU 9871832 A, IL 111579 A, NO 307364 B1, AU 726758 B, US 6180657 B1, SG 77569 A1, RU 2160101 C2

L1: Entry 30 of 30

File: DWPI

Sep 12, 2001

DERWENT-ACC-NO: 1995-201855

DERWENT-WEEK: 200158

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Use of melatonin derivs. - to treat desynchronisation disorders resulting from irregular patterns of sleep, food and drink appetite etc.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Clip Img	Image							

KMIC

[Generate Collection](#)[Print](#)

Terms	Documents
melatonin same food	30

Display Format:[Change Format](#)[Previous Page](#)[Next Page](#)

WEST Search History

DATE: Monday, March 11, 2002

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
L1	melatonin same food	30	L1

END OF SEARCH HISTORY